Information presented at the 61st Annual Meeting of the American Academy of Neurology (April, 2009) indicates that glutamate receptors may play a role in Migraine treatment.

Trial Phase IIa data showed Addex Pharmaceuticals' ADX10059, an investigational glutamate receptor inhibitor, could prove helpful for Migraine prevention. Other early trials have shown ADX1005 to be an effective abortive treatment for acute migraine attacks.

Glutamate is a neurotransmitter, a chemical occurring...